Characterization of nonrandom chromosomal gains and losses in multiple myeloma by comparative genomic hybridization

被引:116
作者
Cigudosa, JC
Rao, PH
Calasanz, MJ
Odero, MD
Michaeli, J
Jhanwar, SC
Chaganti, RSK
机构
[1] Mem Sloan Kettering Canc Ctr, Cell Biol & Genet Program, New York, NY 10021 USA
[2] Mem Sloan Kettering Canc Ctr, Dept Human Genet, New York, NY 10021 USA
[3] Mem Sloan Kettering Canc Ctr, Dept Med, New York, NY 10021 USA
[4] Univ Navarra, Dept Genet, E-31080 Pamplona, Spain
关键词
D O I
10.1182/blood.V91.8.3007.3007_3007_3010
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Clonal chromosomal changes in multiple myeloma (MM) and related disorders are not well defined, mainly due to the low in vivo and in vitro mitotic index of plasma cells. This difficulty can be overcome by using comparative genomic hybridization (CGH), a DNA-based technique that gives information about chromosomal copy number changes in tumors. We have performed CGH on 25 cases of MM, 4 cases of monoclonal gammopathy of uncertain significance, and 1 case of Waldenstrom's macroglobulinemia. G-banding analysis of the same group of patients demonstrated clonal chromosomal changes in only 13 (43%), whereas by CGH, the number of cases with clonal chromosomal gains and losses increased to 21 (70%). The most common recurrent changes detected by CGH were gain of chromosome 19 or 19p and complete or partial deletions of chromosome 13. +19, an anomaly that has so far not been detected as primary or recurrent change by G-banding analysis of these tumors, was noted in 2 cases as a unique change. Other recurrent changes included gains of 9q, 11q, 12q, 15q, 17q, and 22q and losses of 6q and 16q. We have been able to narrow the commonly deleted regions on 6q and 13q to bands 6q21 and 13q14-21. Gain of 11q and deletion of 13q, which have previously been associated with poor outcome, can thus be detected by CGH, allowing the use of this technique for prognostic evaluation of patients, without relying on the success of conventional cytogenetic analysis. (C) 1998 by The American Society of Hematology.
引用
收藏
页码:3007 / 3010
页数:4
相关论文
共 22 条
[21]   CYTOGENETIC STUDY IN MULTIPLE-MYELOMA AT DIAGNOSIS - COMPARISON OF 2 TECHNIQUES [J].
SMADJA, NV ;
LOUVET, C ;
ISNARD, F ;
DUTEL, JL ;
GRANGE, M ;
VARETTE, C ;
KRULIK, M .
BRITISH JOURNAL OF HAEMATOLOGY, 1995, 90 (03) :619-624
[22]   POOR-PROGNOSIS IN MULTIPLE-MYELOMA IS ASSOCIATED ONLY WITH PARTIAL OR COMPLETE DELETIONS OF CHROMOSOME-13 OR ABNORMALITIES INVOLVING 11Q AND NOT WITH OTHER KARYOTYPE ABNORMALITIES [J].
TRICOT, G ;
BARLOGIE, B ;
JAGANNATH, S ;
BRACY, D ;
MATTER, S ;
VESOLE, DH ;
NAUCKE, S ;
SAWYER, JR .
BLOOD, 1995, 86 (11) :4250-4256